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Summary Insulin and the insulin-like growth factors (IGFs) may be important regulators of breast cancer
growth. The IGF-II receptor is identical to the mannose 6-phosphate (Man-6-P) receptor, which is involved in
lysosomal enzyme pathways. In order to determine whether the Man-6-P/IGF-II receptor gene copy number is
altered in breast cancer we analysed specimens of invasive breast carcinoma from 51 patients by Southern
blotting. No amplification of the receptor gene was observed whatever the clinical presentation of the tumour
and irrespective of a concomitant amplification of c-erbB2 or int-2 genes in several tumours. As indicated by
Northern blotting, the gene is transcribed in breast tumour tissues and non-tumour breast tissue. These results
suggest that the receptor gene is stable in breast carcinoma and that, if anything, the receptor involvement in
breast cancer progression may be the result of a disregulation of its expression at a post-transcriptional or
post-translational level.
Experimental data suggest that insulin and the insulin-like
growth factors (IGFs) may be important regulators of breast
cancer growth (Yee, 1992). IGF-II is mitogenic for several
breast tumour cell lines, and IGF-II mRNA has been found
in some breast primary carcinomas as well as in several
breast tumour cell lines (Osborne et al., 1989, 1990; Cullen et
al., 1991; Manni et al., 1992; Paik, 1992). Morgan et al.
(1987) reported that the sequence of the human insulin-like
growth factor II (IGF-II) receptor corresponds to that of the
bovine calcium-independent mannose 6-phosphate receptor,
thus establishing that this receptor is a multifunctional pro-
tein. The finding that this receptor binds both IGF-II and
Man-6-P-bearing lysosomal enzymes suggested that this
receptor may be involved in the clearance of IGF-II from
circulation, in the modulation of trafficking of lysosomal
enzymes such as cathepsin D, a protease present in breast
carcinoma tissue and possibly involved in matrix degradation
or in signal transduction (Kornfeld, 1992). The intra-tumour
level of cathepsin D in breast cancer seems to bear a pre-
dictive value on the occurrence of distant metastases (Tandon
et al., 1990; Rochefort, 1992).
Breast cancer cells are thus able to synthesise and to
secrete in vitro two different mitogenic molecules, cathepsin
D and IGF-II, which bind the same Man-6-P/IGF-II recep-
tor (Vignon & Rochefort, 1992). The functional aspects of
the receptor have not been fully investigated in tumours
because IGF-II binds to IGF-binding proteins (for recent
reviews see Krywicki & Yee, 1992; Figueroa & Yee, 1992)
and less specifically to other receptors, such as IGF-I recep-
tor and insulin receptor (Humbel, 1990), both present and
expressed in breast carcinoma. However, circumstantial
evidence suggests that the receptor might have a role in the
biology of breast cancer: a quantitative study has shown that
the Man-6-P/IGF-II receptor mRNA is present in breast
cancer tissues (Cullen et al., 1990) and the receptor protein
has been detected in several breast cancer cell lines (De Leon
et al., 1988).
These observations prompted us to look for amplification
of the mannose 6-phosphate receptor gene, since other
growth factor receptor genes are often amplified in breast
cancer (Van de Vijver & Nusse, 1991). We report in this
paper the results obtained from examination of 51 breast
tumour tissue specimens and three non-tumour breast tissue
specimens for Man-6-P/IGF-II receptor gene copy number.
We did not observe amplification of the Man-6-P/IGF-II
receptor gene in any specimen, even in conditions where
amplification of other genes (c-erbB2, int-2) was present. The
receptor gene is transcribed in tumour as well as in non-
tumour tissue. These data suggest that the receptor gene is
stable and that any involvement in breast cancer progression
may be the result of a modification of its expression at a
post-transcriptional or post-translational level.
Materials and methods
Patients andpathological material
Tissue specimens were obtained during surgery, washed in
saline and immediately frozen in liquid nitrogen. Specimens
of invasive carcinoma were obtained from 51 patients treated
for breast cancer at the University Hospital of Tours. The
types of investigation, histopathological type classification
and prognostic grades, stage of the disease, therapeutic steps,
and follow-up have already been described (Bougnoux et al.,
1991). The tumour was predominantly of the ductal type in
41 patients, lobular in three patients and of other types in the
remaining patients. Two specimens were from local relapses,
within breast tissue that had received radiation therapy
(65 Gy). As reference, control tissues were also analysed: a
fibroadenoma, a non-proliferative dysplasia, a portion of
non-tumour tissue close to a carcinoma and two specimens of
placenta from voluntary abortion products at 7.5 and 8
weeks of pregnancy.
DNA and RNA extraction
Genomic DNA was prepared from frozen powdered tissue by
phenol extraction (Sambrook et al., 1989). After ethanol
precipitation, the DNA samples were dissolved in 10 mM Tris
- 1 mM EDTA (pH 7.4) and stored at - 20°C. Total RNA
was extracted as previously described (Chomczynski & Sac-
chi, 1987), redissolved in 10 mM Tris buffer, pH 7.5, and
stored at - 70°C.
Probe
The 7.9-kb XbaI/SalI fragment of Man-6-P/IGF-II receptor
cDNA was excised from the pGEM-MPR8 kindly supplied
by Dr W.S. Sly (St Louis University School of medicine, St
Louis, MO, USA) and radiolabelled with [a-32P]dCTP
(3000 Ci mmol-1) by the random primer method of Feinberg
and Vogelstein (1984). For Southern blot analysis of c-erbB2
the plasmid pSV2-erbB2 (Yamamoto et al., 1986) was digested
to completion with HindIII to release the full-length 4.4-kb
c-erbB2 cDNA, which was radiolabelled by the above-
mentioned technique. The probe used to visualise the int-2
locus corresponded to a 0.9-kb Sacl fragment (designed SS6)
that spans the presumptive second exon of the human gene
(Casey et al., 1986). We used actin cDNA (Minty et al.,
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1981) and a-satellite DNA (Gray et al., 1985) for control of
DNA loading and actin cDNA for control of RNA loading
and quality.
DNA analysis
Ten micrograms of DNA was digested with EcoRI and XbaI
and electrophoresed through a 0.8% agarose gel. The DNA
was blotted onto Hybond-N membrane (Amersham, Buck-
inghamshire, UK) and cross-linked by alkaline treatment of
the membrane in 0.4 M sodium hydroxide. Hybridisation was
performed according to the method of Mahmoudi and Lin
(1989): briefly, the membrane was hybridised at 68°C over-
night with 2 x 106 c.p.m. ml-' radiolabelled probe in phos-
phate buffer 1 M, 20% SDS, 15% bovine serum albumin
(BSA), 0.5M EDTA and 10 mgml-' denaturated sonicated
salmon sperm DNA. The blot was then washed to high
stringency (0.2 SSC at 68°C) and autoradiographed for 1-3
days at -70°C using Fuji medical X-ray film.
RNA analysis
Total RNA (50 jg per lane) was separated by electrophoresis
in glyoxal gels (1.4% agarose), transferred to nylon mem-
branes, hybridised with the X-32P-labelled mannose 6-phos-
phate/IGF-II receptor or actin cDNA probe, and washed
according to the above-described method for DNA
analysis.
Densitometric scanning ofthe gels
Quantification of the intensities of the autoradiographs was
carried out using a Bioprofil densitometric scanning
apparatus (Vilbert-Lourmat, France).
Results
Southern blot ofbreast cancer tissues DNA
DNA isolated from primary breast tumours was analysed
with a Man-6-P/IGF-II receptor cDNA probe. The digestion
pattern obtained from Southern blotting analysis of nine of
the tumour DNA samples (lanes 1-9) and four non-tumour
tissues, a fibroadenoma (lane 10), a non-proliferative dys-
plasia (lane 11), a non-tumour tissue close to a carcinoma
(lane 12) and a 7.5 weeks' gestation placenta (lane 13) is
presented in Figure 1. Several restriction fragments of the
Man-6-P/IGF-II receptor gene were visible. The pattern
obtained was representative of all the samples examined,
either tumour or reference non-tumour tissues. The differ-
ences in intensity between the fragments of different lanes
reflected the differences in loading of tumour DNA as con-
trolled by the densitometric scanning of the blot compared
with the densitometric scanning after rehybridisation with the
actin cDNA probe (data not shown) and with a-satellite
DNA (Figure 2). No amplification ofthe receptor was detect-
able in the 51 tumour DNA samples.
In order to ensure that the tumours analysed were repre-
sentative of breast cancer, c-erbB2 and int-2 genes, two genes
known to display amplification in a number of breast
tumours, were investigated in the breast tissues investigated
for Man-6-P/IGF-II receptor gene copy number (Figures 3
and 4). Figure 3 shows the results obtained from Southern
blotting analysis of 11 of the tumour DNA samples and of
two non-tumour breast DNA samples. Moderate amplifi-
cation of the 7-kb c-erbB2 fragment was seen in some
tumours (lanes 3, 11 and 14). A high level of amplification
was observed in lane 10. Figure 4 shows the results obtained
from Southern blotting analysis of 14 tumour DNA samples:
amplification of the 6-kb int-2 fragment was detected in some
tumours (lanes 1-3, 13 and 14). The total number of tumour
tissues investigated was 36 for c-erbB2 and 25 for int-2; eight
and three tumours had a gene amplification. The number of
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Figure 1 Southern blot analysis comparing the gene copy
number of Man-6-P/IGF-11 receptor in breast tumour tissues, in
breast non-tumour tissues and in placenta tissue. Tumour (lanes
1-9) and non-tumour (lanes 10- 13) DNAs were digested with
EcoRI and XbaI and hybridised to a 32P-labelled Man-6-P/IGF-II
receptor cDNA probe (see text for details).
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Figure 2 Autoradiography of the Figure 1 blot hybridised with a
32P-labelled a satellite DNA.
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Figure 3 Southern blot analysis comparing the gene copy
number of c-erbB2 in breast tumour and in breast non-tumour
tissues. Tumour (lanes 2-4 and 6-13) and non-tumour (lanes 1
and 5) DNAs were digested with EcoRI and XbaI and hybridised
to a 32P-labelled c-erbB2 cDNA probe.122 E. HEBERT et al.
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Figure 4 Southern blot analysis comparing the gene copy
number of int-2 in breast tumour tissues. DNAs were digested
with EcoRI and XbaI and hybridised to a 32P-labelled int-2 DNA
probe.
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patients with gene amplification according to prognositic fac-
tors is presented in Table I.
Northern blot
We analysed total RNA of 15 of the mammary tumours
analysed above and one non-tumour breast tissue. An appar-
ently normal size 9-kb transcript (Oshima et al., 1988) was
detected when total cellular RNA was subjected to Northern
blot analysis. Figure 5 shows the result for two breast
tumour tissues (Figure 5a, lanes 1 and 2) and non-tumour
breast tissue (Figure 5a, lane 3) using XbaI/SalI fragment of
Man-6-P/IGF-II receptor cDNA as a probe. In order to
control for slight differences in loading of tumour RNA and
for RNA degradation, all membranes were rehybridised with
actin cDNA (Figure Sb, lanes 1-3). The same slight differ-
ences in RNA signals were observed in the two hybridisation
experiments (Figure 5a and b).
Table I Comparative amplification ofMan-6-P/IGF-II receptor gene
with c-erbB2 and int-2 genes in invasive breast carcinoma
Man-6-P/IGF-II c-erbB2 int-2
Prognosticfactor na Amplifb na Ampfb na Amplfb
Age (years)
<45 12 0 10 1 8 0
>45 39 0 26 7 17 3
Stage
I 10 0 7 0 6 2
II 23 0 14 4 8 1
III 17 0 14 4 10 0
NA 1 0 1 0 1 0
Axillary lymph nodesc
Negative 14 0 11 2 9 2
Positive 19 0 13 2 10 1
NA 18 0 12 4 6 0
Histological grade
I or II 30 0 17 2 11 2
III 17 0 15 5 10 1
NA 4 0 4 1 4 0
Vascular invasion
Absent 33 0 24 4 17 3
Present 12 0 10 4 6 0
Unknown 6 0 2 0 2 0
Oestrogen receptor
<10 fmol mg-' 8 0 6 3 6 0
>10fmolmg'I 43 0 30 5 19 3
aNumber of tumours examined. bNumber of tumours with gene
amplification. cPathological status. NA, not applicable.
Figure 5 Northern blot analysis of breast tumour (lanes 1 and 2)
and breast non-tumour tissues (lane 3). Total RNAs were electro-
phoresed in glyoxal-agarose gels as described in Materials and
methods. A Man-6-P/IGF-II receptor transcript of 9 kb was
detected when membranes were hybridised with a Man-6-P/IGF-
II receptor cDNA probe (pattern a) and an actin transcript of
2 kb was detected with an actin cDNA probe (pattern b).
Discussion
The data reported indicate that no amplification of the Man-
6-P/IGF-II receptor gene took place in the tumour tissues of
a set of 51 breast cancer patients. This observation was
found independently of the clinical presentation of the
tumour and irrespective of a concomitant amplification of
c-erbB2 and int-2 genes in several tumours. Tumours are
known to be heterogeneous. First, within the same tumour
tissue sample some tumour cells can be found at different
stages of tumour progression, therefore displaying different
abnormalities. Second, tumour cells are annexed with stroma
cells derived from the host, which in contrast are not
expected to present such genomic abnormalities. Therefore,
in these conditions, the simultaneous amplification of
oncogenes such as c-erbB2 or int-2, along with the lack of
amplification of the Man-6-P/IGF-II receptor gene, strongly
argues against any underestimation of a potential amplifi-
cation of the gene. In addition, the lack of amplification of
the receptor gene is supported by the fact that the intensity
of the tumour DNA signal is very similar to that of non-
tumour tissues (Figure 1).
It is improbable that the results presented represent biased
selection of the tumour samples analysed for the following
reasons. First, the distribution of patients according to age,
stage and pathological type or prognostic grade is close to
the usual presentation of breast cancer (Henderson et al.,
1989). There was, however, some selection in favour of
tumours of large size, because of the need for adequate
material for analysis. Hence our series is enriched in larger
tumours and contains a higher than usual proportion of
patients with either positive axillary lymph nodes or of un-
known lymph node status (since patients with tumours larger
than 30mm at presentation had a surgical biopsy of their
tumour, prior to adjuvant chemotherapy, and no axillary
dissection). This case selection would indicate that the
tumours that we analysed were actually at an advanced
rather than an early stage of tumour progression, and
therefore perhaps more prone to possess genetic abnor-
malities than tumours obtained at earlier stages of the
disease. Secondly, we found that 22% and 12% of theIGF-IIR GENE COPY NUMBER IN BREAST CARCINOMA 123
tumour specimens examined had an amplification of c-erbB2
and int-2 respectively. This is in line with results already
reported, with a range of 20-30% for the frequency of
amplification for c-erbB2 (Slamon et al., 1987), and of less
than 20% for int-2 (Lidereau et al., 1988). In addition, all
tumours with int-2 gene amplification were oestrogen recep-
tor positive, an observation previously reported (Borg et al.,
1991). These findings suggest that the lack of amplification of
Man-6-P/IGF-II receptor along with an amplification of
other genes is likely to reflect a phenomenon specific to this
gene.
The analysis of the receptor RNA level in some tumours
and one non-tumour tissue indicates that the receptor gene is
transcribed in all the tissues examined. We have not
measured the level of the receptor protein product because of
limited availability of tumour tissues. Therefore we cannot
rule out the possibility that post-transcriptional or post-
translational mechanisms could lead to a modification of
expression of the receptor in breast cancer as has been
observed in thyroid neoplasms (Yashiro et al., 1991).
It is widely accepted that multiple genetic alterations are
essential for the development of malignant tumours, includ-
ing human breast cancer. The gene alterations that have been
found in human breast cancer are mostly amplifications of a
small number of oncogenes. Other growth factor receptors
not strictly defined as oncogenes may be good candidates for
amplification in breast cancer. Indeed the IGF-I receptor,
which has been shown to have prognostic value (Peyrat &
Bonneterre, 1992), was reported to be sporadically amplified
in breast cancer (Berns et al., 1992). Some human cell lines
contain increased quantities of the insulin receptor protein
although its gene is not amplified or overexpressed (Milazzo
et al., 1992).
The Man-6-P/IGF-II receptor molecules in the trans Golgi
network play an essential role in lysosomal enzyme traffick-
ing, and this may explain the stability of its gene. Further
experiments, such as immunolocalisation of the receptor pro-
tein, are required to clarify its role if any in breast cancer
growth.
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